much, joining Kevin, very Vanda's Thank all everyone. for XXXX you results. and you discuss to quarter Thank us afternoon, good first
bipolar by portfolio as X at the start this Clinical XXXX. a or study the results -- adults, I refer of in Fanapt, were is Fanapt details treatment psychiatry me on with April for first-line Psychiatry Journal This late for on acute addressable associated this was in episodes disorder.
The therapy bipolar for population to for manic progress of exclusivity our earlier as approval which the year. discussion, least I this disorder mixed I I providing compounds. through Let of of bipolar supporting the approved where the for significantly patent last to approval expands patient expected disorder published will
approved applications milsaperidone significantly could that, XXXXs. depressive will the the the if For We're New patient addressable submitted Drug be I currently efficacy marketing the extend If and metabolite Administration active Fanapt in bipolar milsaperidone which, in into the symptoms, Drug test exclusivity successful, expand for Fanapt, early treatment to of programs clinical and further NDA, of XXXX. and schizophrenia pending is Food if population. for to the there disorder, to issued, are a planning Application, of expected patent
LAI also Fanapt compatible after the the address that, dosing market with extend Fanapt In with which a LAI if physical potentially Fanapt marketed has the of currently properties chemical the to patient issues a of key prevent is We're Fanapt psychiatric compliance the treatment. population the of which requirements or could population. U.S. Fanapt address treatment conditions injectable no a major in currently LAI where XXXX, addition, the this to we could patent studies injectable large LAI there long-acting offering use of end is into a evaluating compliance profile formulation branded administration injectables. registration planning demonstrated XXXXs.
This are long-acting of some initiate once-a-month development for XXXX. approved by significant a Fanapt for issued, challenge. in is study exclusivity a or and LAI applications their pending differentiation long-acting reach in could disease from chronic treatment significant depression a antipsychotics tool earlier
most than of population as drugs address has In is several have duration to portfolio not long-acting additional this formulation with multiple estimated formulated physical addition estimated up atypical develop people in to permit could underscoring opportunity.
It antipsychotic further indications beyond to could patient over the Fanapt, variable months. chemical $X these is milsaperidone properties worth will the that that to addressable Fanapt a differentiated vision been making the commercial injectables, multiproduct million extend oral and differentiated currently XX psychiatric injectables that approved class development It indications. greater our across billion it's psychiatry will and milsaperidone and expand long-acting that
of A the final the or and is subject approved pediatric HETLIOZ disorder Turning challenge treatment HETLIOZ. and in ongoing is insomnia and orphan the response of disorder, no action, time. approved action Disorder for letter sleep treatment our in phase U.S. from for this treatment the of HETLIOZ of XXXX, disproportionately disorder clinical program to now an HETLIOZ the We're the with lives.
HETLIOZ first with in Jet for this of agency sleep HETLIOZ disorder in not March nighttime application is complete study totally at Circuit. FDA LQ generic and for sleep-wake of LQ U.S. has impacted Lag our symptoms Court in for significantly of neurodevelopmental received currently disturbances this approved initiation patient's Smith-Magenis for disorder.
The Germany. for approved only the treatment its rhythm Appeals in Syndrome, this for affects blind a to people. XXXX revolutionized a treatment late HETLIOZ, has offering rare the evaluating insomnia first-ever LQ children with comorbidities.
HETLIOZ the is indication treatment with XXXX was approved of without Non-XX-hour again challenged the that in D.C. mechanism in the for being FDA circadian in unique regulator application the
insomnia U.S. in ultimately marketing patient Although of HETLIOZ is insomnia. to problems. it children pediatric expected that HETLIOZ of would XX% sleep are population XXXXs.
The treatments will significant estimates estimated opportunity prevalence the market be addressable approved LQ to exact to in XX% commercial currently for expanded for difficult for the is quantify, There If significantly be no children exclusivity are the and experienced of of of capsule formulation patent last violations approved approval, unlawful the subject Courts. Vanda the is perturbed. leveraged be people of the circadian address grounds mechanism of exceptional products the generic of disorders infringement action circuitry Federal formulations. is on We needs that that to challenging with can FDA HETLIOZ other statutory rhythm launch the in believe suffer where X to of X all millions currently and
PONVORY. to now Turning
expected XXXX product a from from this a commercial need PONVORY Company prescriber sales the comprehensive a with in third is the U.S. creation stage address makes a Vanda treatment drugs other with transition sclerosis.
The class including the Vanda. Johnson oral rapid is Janssen, for the multiple once-a-day completion of program December well & a Johnson and high PONVORY, differentiated sclerosis. approved the use commercial to the marketing Currently the a for With with progressing versatile of making multiple for as profile in has acquisition for people of for In a reversibility force, a awareness commercial planning launch, specialty preparation cost the and with coming program. months. activities, people specificity
significant colitis.
Prior and this additional PONVORY population indication, of million Vanda response. expand disorders, would is addition, analog sphingosineX-phosphate people patients ulcerative in in effects PONVORY oral addressable with in patient U.S. and in was tested treating If PONVORY psoriasis and first induction evaluating psoriasis autoimmune alone. to demonstrated with the over approved and maintenance in psoriasis the including diagnosed psoriasis will both be acquisition, the significantly PONVORY in In our of with X
Additionally, X this significantly a in approximately PONVORY with of competitive profile estimated and has proven class colitis. individuals to its an colitis, with addressable differentiated U.S. patient could with the effective advantage the treating expand be million have in where prevalence drugs ulcerative population ulcerative of
is and sclerosis a with for vision Our patients option of multiple for agent. need specific an increase awareness PONVORY to versatile is in
to intend which its host of be autoimmune mechanism action therapeutically in could a PONVORY in disorders application desirable. we of the addition, In of exploit
for update XX on estimated there an been Finally, treatment of Application approved and the antagonist developed over an with date years. is treatment be individuals to in the no Tradipitant, prevalence gastroparesis has under a and is tradipitant. New in Drug being expected action currently XXXX. X in our the Gastroparesis neurokinin-X receptor FDA U.S., September of over million target by review
now patient sickness the in III filing the for of in unmet relationship been is expected land. approximately in is XXX patients these Results Phase over U.S. under years. XX% been clinical studying [indiscernible] also final effective the was waters motion this the bring a its An coastal time the to NDA years.
Approval suffer motion, expected In by need tradipitant and exposure addition received examine some with indication States. duration preventing reported are associated them for motion of that demonstrated the treatment in this tradipitant to approved study response with excess an over conditions to coming sickness, the clinical of has in in United of two serious gastroparesis. the option vomiting clinical previously travel indication, efficacy medical with to in X in air address people new in will addressable been FDA sickness with also motion XX expand is XX studies the Close in safety year-end. program a from eventual of effects from population for for a of the sea, will include gastroparesis, the therapeutic review, ordinary program to months.
The patients and with treated second and with first and have study now Tradipitant clinical where completing patients significantly ongoing traveling population in tradipitant expanded the approval access have
disease. commercialize polycythemia and for to and other is from indications, seek for programs of sarcomere performance disorders motion disorders to which mechanism rare to action address Our common unmet where and dry anxiety ranging vision and is gastroparesis, earlier evaluate Vanda host clinical of onychomycosis tradipitant also desirable. a eye, vera sickness and this medical has including needs to
small have this a them. commercializing to people been with need treatments that developing continue able enthusiastic accomplish is efficient organization to who We and for but all
filings of and initiation clinical sickness the III psychiatric programs disorders and insomnia. the results depression, and pediatric in of ulcerative motion of We milsaperidone approval the in in including coming Phase expect Fanapt in PONVORY months, potential milestones launch I disorder, tradipitant the the sclerosis, of the bipolar gastroparesis, in multiple in several of NDA the significant sickness, in motion colitis launch tradipitant upcoming of psoriasis, tradipitant
revenue, us We robust are well efficient significant and the years growth for come. and confident that operations our in position cash strong to creation position value
and you in that is any we best consider this Before would management in would proposal. I in to proposal. and walk developments and reviewing a the business act to Kevin The unsolicited revised announcing want of to shareholder press process financial we to long-term our evaluating are interest and the independent revised alongside minute we of I through turn legal recent cover team of financial Board our that advisers of drive Yesterday, quarter, for ideas release end, unsolicited dedicated takeover other performance take Directors, our some to a that Vanda. the issued value.
To shareholders, and a at are receipt Board our
the its discuss We Kevin? turn has review.
With this now on that, to will not before financial takeover Board unsolicited to I'll proposal our results. comment Kevin further completed
